Table 5.
Detection rates for GM injuries and H. pylori according to the administration of drugs.
| Patient groups receivingdrugs at the time of study inclusion, n = 73 | |||||||
|---|---|---|---|---|---|---|---|
| Drugs | H. pylori | Altered gastric mucosa, | Intact gastric mucosa, | P; OR; 95% CI | |||
| n = 69 | n = 4 | ||||||
|
| |||||||
| Glucocorticoids, n (%) | (+) | 43 (62.3) | 30 (69.8) | 1 (100.0) | 1 (25.0) | P 1 = 0.0059; OR = 21.50; 95% CI 2.12-218.27 | P2 = 0.70; OR = 0; 95% CI 0-NaN |
| (-) | 13 (30.3) | 0 | |||||
|
| |||||||
| ACs, n (%) | (+) | 47 (68.1) | 41 (87.2) | 1 (50.0) | 2 (50.0) | P 1 = 0.011; OR = 11.75; 95% CI 1.84-75.15 | P2 = 0.27; OR = 6.83; 95% CI 0.38-124.34 |
| (-) | 6 (12.8) | 1 (50.0) | |||||
|
| |||||||
| LDASA, n (%) | (+) | 37 (53.6) | 33 (89.2) | 2 (66.7) | 3 (75.0) | P 1 = 0.041; OR = 6.17; 95% CI 1.15-33.11 | P2 = 0.34; OR = 4.13; 95% CI 0.30-56.39 |
| (-) | 4 (10.8) | 1 (33.3) | |||||
|
| |||||||
| NSAID+LDASA, n (%) | (+) | 19 (27.5) | 13 (68.4) | 0 | 1 (25.0) | P 1 = 0.05; OR = 9.5; 95% CI 0.91-98.81 | P2 = 0.35; OR = 0 95% CI 0 |
| (-) | 6 (31.6) | 1 (100.0) | |||||
|
| |||||||
| Patient group not receiving GCs, ACs, LDASA, NSAID + aspirin for 6 months or more (comparison group); n = 12 | |||||||
|
| |||||||
| No drugs, n (%) | (+) | 8 (66.7) | 5 (62.5) | 2 (50.0) | 4 (33.3) | P 1 | - |
| (-) | 3 (37.5) | 2 (50.0) | |||||
Notes: LDASA – low-dose acetylsalicylic acid; NSAID – nonsteroidal anti-inflammatory drugs; ACs – anticoagulants. The percentage of patients with altered or intact GM was calculated from the number of all the patients in group.
The percentage of H. pylori-positive patients was calculated from the number of those in the group receiving the appropriate drug.
P1 - comparison of the number of patients with and without GM changes who took the appropriate drug with that in the comparison group.
P2 - comparison of the number of patients taking the appropriate drug and having and not having GM changes according to the presence or absence of H. pylori.